Dymista® is included in the British Society of Allergy and Clinical Immunology (BSACI) Rhinitis Guidelines as a treatment option for allergic rhinitis patients
Dymista® is recommended for use as part of a stepwise pharmacological treatment algorithm by both the BSACI and the Stirling Consensus.1,2 The BSACI guidelines were produced via a NICE accredited process by the Standards of Care Committee.1
Combination of topical antihistamine (AH) with intranasal corticosteroids (INS) Dymista® should be used in patients when symptoms remain uncontrolled on AH or INS monotherapy or on a combination of oral AH plus INS1
Adherence with this care pathway has the potential to limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases.2
BSACI Guideline - Dymista® leads to greater symptom improvement than azelastine or fluticasone propionate (FP) alone1
Click below to learn more about Dymista®'s position in the BSACI Rhinitis Guidelines
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Scadding GK, et at BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017, First edition 2007). Clin Exp Allergy 2017; 47(7): 856–889.
- Lipworth B, et al. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27(1)